Table 2.

Association of patient- and tumor characteristics with progression-free and overall survival (univariate analysis)

	PFS	OS
	HR (95% CI)	HR (95% CI)
Age, years*(for every additional year)	1.02 (1.004–1.04), P = 0.014	1.04 (1.02–1.06), P < 0.001
Sex (male vs. female)	1.24 (0.80–1.91), P = 0.345	1.40 (0.82–2.40), P = 0.213
ECOG at admission* (for 1-point increase in grade)	1.55 (1.20–1.99), P = 0.001	1.55 (1.23–1.95), P < 0.001
Extent of resection
GTR vs. biopsy*	0.28 (0.16–0.47), P < 0.001	0.15 (0.08–0.30), P < 0.001
STR vs. biopsy*	0.44 (0.25–0.74), P = 0.002	0.29 (0.16–0.54), P < 0.001
GTR vs. STR	0.64 (0.38–1.07), P = 0.088	0.53 (0.26–1.07), P = 0.077
Radiology
Ring-enhancement vs. no	2.34 (0.98–5.57), P = 0.056	2.01 (0.59–6.84), P = 0.266
Midline shift	1.02 (0.66–1.57), P = 0.933	0.81 (0.48–1.37), P = 0.432
Multifocal tumor*	0.83 (0.51–1.36), P = 0.454	2.32 (1.40–3.90), P = 0.001
WHO Grade
WHO grade II vs. III	0.82 (0.49–1.38), P = 0.459	0.59 (0.31–1.11), P = 0.103
Molecular markers
MGMT methylated vs. unmethylated	0.78 (0.49–1.24), P = 0.293	0.93 (0.55–1.58), P = 0.784
ATRX lost vs. retained	0.43 (0.17–1.07), P = 0.070	0.48 (0.15–1.56), P = 0.224
EGFR expression
No vs. strong	0.44 (0.15–1.24), P = 0.120	0.22 (0.07–0.70), P = 0.011
No-moderate vs. strong*	0.30 (0.11–0.81), P = 0.017	0.16 (0.05–0.47), P = 0.001
TERT mutation vs. wild-type*	1.65 (0.59–4.63), P = 0.34	7.85 (1.03–59.7), P = 0.047
Treatment
Radiochemotherapy, according to Stupp vs. other treatment	0.98 (0.51–1.91), P = 0.960	0.79 (0.39–1.58), P = 0.498
Perioperative complication*	1.42 (0.75–2.69), P = 0.281	2.49 (1.39–4.47), P = 0.002

Cox regression, asterisk marks statistically significant variables.